Page last updated: 2024-10-23

benzocaine and Pain

benzocaine has been researched along with Pain in 51 studies

Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.
dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.
benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.

Pain: An unpleasant sensation induced by noxious stimuli which are detected by NERVE ENDINGS of NOCICEPTIVE NEURONS.

Research Excerpts

ExcerptRelevanceReference
"A significant pain reduction was observed following the use of ketoprofen when tested against a control gel (placebo)."9.22The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial. ( Borzabadi-Farahani, A; Eslamian, L; Gholami, H, 2016)
"Benzocaine gel caused a decrease in pain perception at 2 h compared with placebo gel."9.22Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial. ( Eslamian, L; Gholami, H; Mortazavi, SA; Soheilifar, S, 2016)
"This study aims to explore the efficacy of the topical application of 10% benzocaine for treating pruritus and pain as compared to vehicle ointment."9.20A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. ( Bauer, M; Lang-Zwosta, I; Nishino, K; Scherzer, T; Schwameis, R; Zeitlinger, M, 2015)
"In a reference-controlled double-blind trial in patients with acute pharyngitis the effects of a newly developed lozenge containing 8 mg of benzocaine (p-aminobenzoic acid ethyl ester, CAS 94-09-7) were compared with those of an identically dosed commercial pastille."9.14Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis. ( Busch, R; Graubaum, HJ; Grünwald, J; Schmidt, M, 2010)
"Topical application of EMLA and Oraqix before palatal anesthetic infiltration is associated with less pain than with benzocaine gel."9.12Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection. ( Al-Melh, MA; Andersson, L, 2007)
"5% are significantly more effective than 20% benzocaine in reducing pain from needle stick in the maxillary vestibular mucosa."9.11Reduction of pain from needle stick in the oral mucosa by topical anesthetics: a comparative study between lidocaine/prilocaine and benzocaine. ( Abu Al-Melh, M; Andersson, L; Behbehani, E, 2005)
"To compare pain relief in metastatic pancreatic cancer patients between neurolytic celiac plexus block (NCPB) and epidural 5% butamben suspension (EBS), a material-based delivery system of a local anesthetic that produces a long-lasting differential nerve block."9.09Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer. ( Harris, JE; Ivankovich, AD; Lubenow, TR; Nath, HA; Shulman, M, 2000)
"Benzocaine did not affect pain scores for any of the two symptoms, nor did it alter global subjective or objective assessment of therapy outcome in treated compared to untreated subjects (P > 0."9.08Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis. ( Becker, C; Becker, K; Frieling, T; Häussinger, D, 1997)
"If methemoglobinemia is left untreated, it may be fatal."6.44Intraoperative detection of methemoglobinemia in a patient given benzocaine spray to relieve discomfort from a nasogastric tube: a case report. ( Young, B, 2008)
"5 mg benzocaine) provides a rapid analgesic effect and is effective in relieving both severe throat pain as well as difficulty in swallowing associated with acute pharyngitis leading to a 64% improved complete remission within 72 hours."5.27Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha). ( Fuchs, K; Milde, J; Palm, J; Schumacher-Stimpfl, A; Stammer, H, 2018)
"A significant pain reduction was observed following the use of ketoprofen when tested against a control gel (placebo)."5.22The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial. ( Borzabadi-Farahani, A; Eslamian, L; Gholami, H, 2016)
"Benzocaine gel caused a decrease in pain perception at 2 h compared with placebo gel."5.22Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial. ( Eslamian, L; Gholami, H; Mortazavi, SA; Soheilifar, S, 2016)
"This study aims to explore the efficacy of the topical application of 10% benzocaine for treating pruritus and pain as compared to vehicle ointment."5.20A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain. ( Bauer, M; Lang-Zwosta, I; Nishino, K; Scherzer, T; Schwameis, R; Zeitlinger, M, 2015)
"In a reference-controlled double-blind trial in patients with acute pharyngitis the effects of a newly developed lozenge containing 8 mg of benzocaine (p-aminobenzoic acid ethyl ester, CAS 94-09-7) were compared with those of an identically dosed commercial pastille."5.14Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis. ( Busch, R; Graubaum, HJ; Grünwald, J; Schmidt, M, 2010)
"Topical application of EMLA and Oraqix before palatal anesthetic infiltration is associated with less pain than with benzocaine gel."5.12Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection. ( Al-Melh, MA; Andersson, L, 2007)
"5% are significantly more effective than 20% benzocaine in reducing pain from needle stick in the maxillary vestibular mucosa."5.11Reduction of pain from needle stick in the oral mucosa by topical anesthetics: a comparative study between lidocaine/prilocaine and benzocaine. ( Abu Al-Melh, M; Andersson, L; Behbehani, E, 2005)
"Topical benzocaine spray does not appear to offer effective pain control in patients undergoing an endometrial biopsy."5.11Topical analgesia for endometrial biopsy: a randomized controlled trial. ( Einarsson, JI; Henao, G; Young, AE, 2005)
"To compare pain relief in metastatic pancreatic cancer patients between neurolytic celiac plexus block (NCPB) and epidural 5% butamben suspension (EBS), a material-based delivery system of a local anesthetic that produces a long-lasting differential nerve block."5.09Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer. ( Harris, JE; Ivankovich, AD; Lubenow, TR; Nath, HA; Shulman, M, 2000)
"Pain generated by needle sticks (Ns) for the delivery of local anesthetic and/or scaling and root planing (SRP) instrumentation is commonly addressed by the use of topical anesthetics, such as a benzocaine-gel preparation (BGP)."5.09Clinical evaluation and comparison of 2 topical anesthetics for pain caused by needle sticks and scaling and root planing. ( Carr, MP; Horton, JE, 2001)
"The effectiveness of lidocaine and benzocaine in reducing pain produced by needle insertion into the palate was evaluated in a double-blind and placebo-controlled study using a more suitable method."5.09Clinical effectiveness of lidocaine and benzocaine for topical anesthesia. ( Lavrador, MA; Rosa, AL; Sverzut, CE; Xavier, SP, 1999)
"To determine the efficacy of Auralgan otic solution (combination product of antipyrine, benzocaine, and glycerin) compared with an olive oil placebo in the management of moderate to severe ear pain in children with acute otitis media (AOM)."5.08Efficacy of Auralgan for treating ear pain in children with acute otitis media. ( Hoberman, A; Paradise, JL; Reynolds, EA; Urkin, J, 1997)
"Benzocaine did not affect pain scores for any of the two symptoms, nor did it alter global subjective or objective assessment of therapy outcome in treated compared to untreated subjects (P > 0."5.08Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis. ( Becker, C; Becker, K; Frieling, T; Häussinger, D, 1997)
"Benzocaine, in a spray vehicle, confers no benefit when used to decrease pain and anxiety in women undergoing colposcopic procedures."5.08Ineffectiveness of topical benzocaine spray during colposcopy. ( Andrews, S; Clifton, PA; Shaughnessy, AF, 1998)
"Butamben (n-butyl-p-aminobenzoic acid) is a pain-relieving local anesthetic for topical use."3.78Inhibition of sensory neuronal TRPs contributes to anti-nociception by butamben. ( Bang, S; Heo, TH; Hwang, SW; Yang, TJ; Yoo, S, 2012)
" In another experiment, the preparation was tested in a further 22 subjects for its pain-relieving effect during a standard palatal injection, and compared with 18% benzocaine/2% tetracaine gel."3.78Relief of palatal injection pain by liposome-encapsulated 2% lignocaine prepared by ultrasonic dental scaler. ( Paphangkorakit, J; Priprem, A; Sangsirinakagul, C, 2012)
"One hundred twelve emergency patients with irreversible pulpitis received long buccal nerve block injections using 2% lidocaine with 1:100,000 epinephrine."3.77Long buccal nerve block injection pain in patients with irreversible pulpitis. ( Beck, M; Drum, M; Reader, A, 2011)
"There was an estimated 75% increased perception of pain on the forearm to which benzoyl peroxide was applied in consort with the topical anesthetic at all examination times."3.73Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide. ( Burkhart, CG; Burkhart, CN, 2005)
" The purpose of this study was to compare the effectiveness of 20% benzocaine in reducing the pain of needle insertion during maxillary posterior and anterior infiltration and inferior alveolar nerve block injections."3.72Effectiveness of 20% benzocaine as a topical anesthetic for intraoral injections. ( Beck, M; Nusstein, JM, 2003)
"The cost of treating postepisiotomy pain and edema with foam containing 1% hydrocortisone acetate and 1% pramoxine hydrochloride and a spray with 20% benzocaine was compared in 200 postpartum patients."3.67Cost analysis of a mucoadhesive foam versus conventional treatment for postepisiotomy patients. ( Bouis, P; Hoffman, M; Johnson, S; Mack, M; Newton, W, 1986)
" Methemoglobin and oxygen saturation levels did not change compared with baseline after dosing with either treatment."2.90A Proof-of-concept Study Using Quantitative Sensory Threshold Analysis to Compare Two Intraoral Topical Anesthetics. ( Cooper, SA; Doyle, G; Farrar, JT; Giannakopoulos, H; Hersh, EV; Hutcheson, MC; Lesavoy, B; Mousavian, M; Secreto, S; Wang, P; Wang, S, 2019)
"If methemoglobinemia is left untreated, it may be fatal."2.44Intraoperative detection of methemoglobinemia in a patient given benzocaine spray to relieve discomfort from a nasogastric tube: a case report. ( Young, B, 2008)
"Benzocaine is a commonly used topical anesthetic present in many over-the-counter preparations."1.31Unexpected cyanosis in the surgical patient. ( Douglass, HO; Lee, JS; Mendez, PA, 2000)
"Chemotherapy-induced oral mucositis can result in inadequate oral intake, local and systemic infection, a prolonged hospital stay, and increased cost of treatment."1.30Treating the discomfort of oral ulceration resulting from cancer chemotherapy. ( Haveman, CW; Redding, SW, 1999)

Research

Studies (51)

TimeframeStudies, this research(%)All Research%
pre-199011 (21.57)18.7374
1990's7 (13.73)18.2507
2000's13 (25.49)29.6817
2010's17 (33.33)24.3611
2020's3 (5.88)2.80

Authors

AuthorsStudies
Shekarchi, F1
Nokhbatolfoghahaei, H1
Chiniforush, N1
Mohaghegh, S1
Haeri Boroojeni, HS1
Amini, S1
Biria, M1
Brignardello-Petersen, R1
Aziz, M1
Ahmed, S1
Qazi, FU1
Naz, F1
Shah, M1
Moorpani, P1
Palm, J1
Fuchs, K1
Stammer, H1
Schumacher-Stimpfl, A1
Milde, J1
Hersh, EV1
Secreto, S1
Wang, S1
Giannakopoulos, H1
Mousavian, M1
Lesavoy, B1
Hutcheson, MC1
Farrar, JT1
Wang, P1
Doyle, G1
Cooper, SA1
Vanuytsel, T1
Karamanolis, G1
Vos, R1
Van Oudenhove, L1
Farré, R1
Tack, J1
Gimovsky, A1
Khodak-Gelman, S1
Larsen, J1
Bachman, EA1
Senapati, S1
Sammel, MD1
Kalra, SK1
Bauer, M1
Schwameis, R1
Scherzer, T1
Lang-Zwosta, I1
Nishino, K1
Zeitlinger, M1
Sandeep, V1
Kumar, M1
Jyostna, P1
Duggi, V1
Eslamian, L2
Borzabadi-Farahani, A1
Gholami, H2
Mortazavi, SA1
Soheilifar, S1
Reznik, DS1
Jeske, AH1
Chen, JW1
English, J1
Busch, R1
Graubaum, HJ1
Grünwald, J1
Schmidt, M1
Puglia, C1
Sarpietro, MG1
Bonina, F1
Castelli, F1
Zammataro, M1
Chiechio, S1
Drum, M1
Reader, A1
Beck, M2
de Melo, NF1
Grillo, R1
Guilherme, VA1
de Araujo, DR1
de Paula, E1
Rosa, AH1
Fraceto, LF1
Bang, S1
Yang, TJ1
Yoo, S1
Heo, TH1
Hwang, SW1
Paphangkorakit, J1
Sangsirinakagul, C1
Priprem, A1
Parirokh, M1
Sadeghi, AS1
Nakhaee, N1
Pardakhty, A1
Abbott, PV1
Yosefi, MH1
Deepika, A1
Rao, CR1
Vinay, C1
Uloopi, KS1
Rao, VV1
Beekwilder, JP1
O'Leary, ME1
van den Broek, LP1
van Kempen, GT1
Ypey, DL1
van den Berg, RJ1
Raymond, P1
Johnson, J1
Primosch, RE1
BAUMANN, J1
PICARD-LEROY, G1
KOHN, J1
RUTTER, AG1
VITALI, M1
GRAHAM, PA1
Nusstein, JM1
Einarsson, JI1
Henao, G1
Young, AE1
Abu Al-Melh, M1
Andersson, L2
Behbehani, E1
Burkhart, CG1
Burkhart, CN1
Al-Melh, MA1
Young, B1
Hoberman, A1
Paradise, JL1
Reynolds, EA1
Urkin, J1
Becker, K1
Becker, C1
Frieling, T1
Häussinger, D1
Clifton, PA1
Shaughnessy, AF1
Andrews, S1
Bouis, P1
Hoffman, M1
Newton, W1
Johnson, S1
Mack, M1
Shulman, M1
Harris, JE1
Lubenow, TR1
Nath, HA1
Ivankovich, AD1
Lee, JS1
Mendez, PA1
Douglass, HO1
Carr, MP1
Horton, JE1
Redding, SW1
Haveman, CW1
Rosa, AL1
Sverzut, CE1
Xavier, SP1
Lavrador, MA1
Gill, CJ1
Orr, DL1
Vickers, ER1
Punnia-Moorthy, A1
Lorino, CO1
Prough, SG1
Aksel, S1
Abuzeid, M1
Alexander, SE1
Wiebe, RH1
Keller, BJ1
Grasser, H1
Ackermann, K1
Weiss, C1
Pande, YN1
Gaynor, HM1
Birke, WP1
Fürtig, W1

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Multi-centre, Randomized, Placebo-controlled, Double-blind, Parallel-group Study Investigating Safety and Efficacy of a Sore Throat Lozenge in the Symptomatic Treatment of Patients With Acute Pharyngitis[NCT03323528]Phase 4321 participants (Actual)Interventional2017-02-01Completed
A Double-blind, Cross-over, Incomplete Factorial Study to Assess the Local Anesthetic Efficacy and Safety of CTY-5339 Anesthetic Spray (CTY-5339A) When Applied to the Gingival Mucosal Tissue in Normal Volunteers[NCT03233737]Phase 275 participants (Actual)Interventional2017-06-15Completed
A Randomized Controlled Trial of Benzocaine Versus Placebo Spray for Pain Relief at Hysterosalpingogram[NCT01925469]Phase 430 participants (Actual)Interventional2011-12-31Completed
Effect of Buzzy System (Vibrating Device) Compared to Topical Anaesthesia on Pain Reduction During Injection of Infiltration Anaesthesia in Children: A Randomized Clinical Trial Study.[NCT05083975]30 participants (Anticipated)Interventional2022-07-23Not yet recruiting
The Effect of Sonophoresis on Topical Anesthesia: a Clinical Trial[NCT01283490]Phase 150 participants (Actual)Interventional2011-02-28Completed
Efficacy of Ethyl Chloride Topical Anesthesia Application on the Pain Perception During Intra-oral Injections in Children in Comparison to Benzocaine Gel- a Single-blinded Randomized Controlled Trial.[NCT06011005]42 participants (Anticipated)Interventional2023-09-01Recruiting
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

Stage I: Duration of Anesthesia as Measured by Heat Sensation Threshold (QST Heat) for One Spray CTY-5339-A Compared to One Spray CTY-5339-CB Compared to One Spray CTY-5339-P (Placebo: Vehicle Control)

"The duration of effect, was defined as the time from onset to treatment failure, as measured by QST Heat score. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. The QST Heat-based Duration of effect was calculated by the length of time in minutes from onset of anesthesia to the absence of anesthesia where Onset of anesthesia was defined by PPT unless specific QST thresholds were not met. After Onset had been established, absence of analgesia or offset was the first of two time points with consecutive occurrences of regression or absence of analgesia. Reports of QST heat pain temperature by ≥ 3 °C of the Baseline QST indicated analgesia; while a report of similar (<3 °C) than Baseline indicated regression or absence of analgesia. Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
Stage I: One Spray CTY-5339-A42.5
Stage I: One Spray CTY-5339-CB6.1
Stage I: One Spray CTY-5339-P5

Stage I: Duration of Anesthesia as Measured by Pin Prick Test (PPT) for One Spray CTY-5339-A Compared to One Spray CTY-5339-CB Compared to One Spray CTY-5339-P (Placebo: Vehicle Control)

"The duration of effect, was defined as the length of time in minutes from onset of anesthesia to the absence of anesthesia.Onset was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than Baseline. Absence of anesthesia was defined as follows: After Onset had been established, absence was the first of two time points with consecutive occurrences of regression of absence of analgesia. Reports of less pain by ≥1 unit than Baseline indicated analgesia; while a report of similar (< 1 unit) or more pain than Baseline indicated regression or absence of analgesia. The minimum onset time was 1 minute. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
Stage I: One Spray CTY-5339-A49.2
Stage I: One Spray CTY-5339-CB21.3
Stage I: One Spray CTY-5339-P25.2

Stage I: Duration of Minimal Pain for Pin Prick Test (PPT) (≤2 on Numerical Rating Scale Pain Scale)

"Response at a time point is defined as having the PPT average pain score of ≤2. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
Stage I: One Spray CTY-5339-A14.5
Stage I: One Spray CTY-5339-CB2.9
Stage I: One Spray CTY-5339-P0.2

Stage I: Onset of Anesthesia for Heat Sensation Threshold (QST Heat)

"Onset of anesthesia was defined by Pin Prick Test (PPT) unless specific QST thresholds were not met.~If the PPT Onset was 5 minutes or less, then QST must have been greater than the Baseline QST temperature at 5 minutes by any amount and QST must have been ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~If the PPT Onset was 10 minutes, then QST must have been ≥ 3 °C of the Baseline QST temperature at 10 minutes.~If PPT did not achieve Onset, then QST alone could have achieved onset at either 5 or 10 minutes if QST was greater than the Baseline QST temperature at 5 or 10 minutes by any amount and the QST was ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
Stage I: One Spray CTY-5339-A2.0
Stage I: One Spray CTY-5339-CB0.4
Stage I: One Spray CTY-5339-P0.8

Stage I: Onset of Anesthesia for Pin Prick Test (PPT)

"Onset of anesthesia was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than the Baseline PPT. Onset was expected to be between 1 and 5 minutes. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
Stage I: One Spray CTY-5339-A1.3
Stage I: One Spray CTY-5339-CB1.2
Stage I: One Spray CTY-5339-P2.8

Stage I: Percentage of Subjects Reaching Maximum Heat for Heat Sensation Threshold (QST Heat)

"QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. Reaching maximum heat for QST Heat was defined as subjects reaching the maximum temperature without reporting pain at one or more time points.~Stage I outcome." (NCT03233737)
Timeframe: Any time within one hour post-application

InterventionParticipants (Count of Participants)
Stage I: One Spray CTY-5339-A5
Stage I: One Spray CTY-5339-CB0
Stage I: One Spray CTY-5339-P0

Stage I: Percentage of Subjects Reaching Minimal Pain on Pin Prick Test (PPT) (≤2 on Numerical Rating Scale Pain Scale)

"Response is defined as a subject having a PPT average pain score of ≤2 recorded at any single time point where PPT was performed. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Any time within one hour post-application

InterventionParticipants (Count of Participants)
Stage I: One Spray CTY-5339-A10
Stage I: One Spray CTY-5339-CB9
Stage I: One Spray CTY-5339-P2

Stage II: Duration of Anesthesia as Measured by Heat Sensation Threshold (QST Heat) for One Spray CTY-5339-A Compared to One Spray CTY-5339-CB

"The duration of effect, was defined as the time from onset to treatment failure, as measured by QST Heat score. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. The QST Heat-based Duration of effect was calculated by the length of time in minutes from onset of anesthesia to the absence of anesthesia where Onset of anesthesia was defined by PPT unless specific QST thresholds were not met. After Onset had been established, absence of analgesia or offset was the first of two time points with consecutive occurrences of regression or absence of analgesia. Reports of QST heat pain temperature by ≥ 3 °C of the Baseline QST indicated analgesia; while a report of similar (<3 °C) than Baseline indicated regression or absence of analgesia. Stage" (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
One Spray CTY-5339-A45.5
One Spray CTY-5339-CB40.8

Stage II: Duration of Anesthesia as Measured by Pin Prick Test (PPT) for One Spray CTY-5339-A Compared to One Spray CTY-5339-CB

"The duration of effect, was defined as the length of time in minutes from onset of anesthesia to the absence of anesthesia.Onset was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than Baseline. Absence of anesthesia was defined as follows: After Onset had been established, absence was the first of two time points with consecutive occurrences of regression of absence of analgesia. Reports of less pain by ≥1 unit than Baseline indicated analgesia; while a report of similar (< 1 unit) or more pain than Baseline indicated regression or absence of analgesia. The minimum onset time was 1 minute. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
One Spray CTY-5339-A14.6
One Spray CTY-5339-CB7.4

Stage II: Duration of Minimal Pain for Pin Prick Test (PPT) (≤2 on Numerical Rating Scale Pain Scale)

"Response at a time point is defined as having the PPT average pain score of ≤2. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
One Spray CTY-5339-A14.6
One Spray CTY-5339-CB7.4

Stage II: Onset of Anesthesia for Heat Sensation Threshold (QST Heat)

"Onset of anesthesia was defined by Pin Prick Test (PPT) unless specific QST thresholds were not met.~If the PPT Onset was 5 minutes or less, then QST must have been greater than the Baseline QST temperature at 5 minutes by any amount and QST must have been ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~If the PPT Onset was 10 minutes, then QST must have been ≥ 3 °C of the Baseline QST temperature at 10 minutes.~If PPT did not achieve Onset, then QST alone could have achieved onset at either 5 or 10 minutes if QST was greater than the Baseline QST temperature at 5 or 10 minutes by any amount and the QST was ≥ 3 °C of the Baseline QST at 5 or 10 minutes.~QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
One Spray CTY-5339-A1
One Spray CTY-5339-CB1.3

Stage II: Onset of Anesthesia for Pin Prick Test (PPT)

"Onset of anesthesia was the time point at which the PPT average pain score was less than the Baseline PPT average score by any amount. Also, in 10 minutes or less, the subject must have had a lower PPT average pain score of ≥ 1 unit than the Baseline PPT. Onset was expected to be between 1 and 5 minutes. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

Interventionminutes (Mean)
One Spray CTY-5339-A1.1
One Spray CTY-5339-CB1.1

Stage II: Percentage of Subjects Reaching Maximum Heat for Heat Sensation Threshold (QST Heat)

"QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point. Reaching maximum heat for QST Heat was defined as subjects reaching the maximum temperature without reporting pain at one or more time points.~Stage II outcome." (NCT03233737)
Timeframe: Any time within one hour post-application

InterventionParticipants (Count of Participants)
One Spray CTY-5339-A7
One Spray CTY-5339-CB5

Stage II: Percentage of Subjects Reaching Minimal Pain on Pin Prick Test (PPT) (≤2 on Numerical Rating Scale Pain Scale)

"Response is defined as a subject having a PPT average pain score of ≤2 recorded at any single time point where PPT was performed. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Any time within one hour post-application

InterventionParticipants (Count of Participants)
One Spray CTY-5339-A50
One Spray CTY-5339-CB50

Stage I: Percentage of Responders for Heat Sensation Threshold (QST Heat) at Each Time Point

"Response at a time point is defined as an increase of QST heat pain temperature by ≥ 3 degrees C compared to the Baseline QST. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Time of application up to one hour post-application

,,
InterventionParticipants (Count of Participants)
Responded to treatment at the 1 minute time pointResponded to treatment at the 2 minute time pointResponded to treatment at the 3 minute time pointResponded to treatment at the 4 minute time pointResponded to treatment at the 5 minute time pointResponded to treatment at the 10 minute time pointResponded to treatment at the 15 minute time pointResponded to treatment at the 20 minute time pointResponded to treatment at the 25 minute time pointResponded to treatment at the 30 minute time pointResponded to treatment at the 35 minute time pointResponded to treatment at the 40 minute time pointResponded to treatment at the 45 minute time pointResponded to treatment at the 50 minute time pointResponded to treatment at the 55 minute time pointResponded to treatment at the 60 minute time point
Stage I: One Spray CTY-5339-A7788899998666666
Stage I: One Spray CTY-5339-CB2333332211100000
Stage I: One Spray CTY-5339-P4444444410000000

Stage I: Percentage of Responders for Pin Prick Test (PPT) at Each Time Point

"Response at at time point is defined as when the PPT average pain score was less than the Baseline PPT average score by any amount. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage I outcome." (NCT03233737)
Timeframe: Time of application up to one hour post-application

,,
InterventionParticipants (Count of Participants)
Responded to treatment at the 1 minute time pointResponded to treatment at the 2 minute time pointResponded to treatment at the 3 minute time pointResponded to treatment at the 4 minute time pointResponded to treatment at the 5 minute time pointResponded to treatment at the 10 minute time pointResponded to treatment at the 15 minute time pointResponded to treatment at the 20 minute time pointResponded to treatment at the 25 minute time pointResponded to treatment at the 30 minute time pointResponded to treatment at the 35 minute time pointResponded to treatment at the 40 minute time pointResponded to treatment at the 45 minute time pointResponded to treatment at the 50 minute time pointResponded to treatment at the 55 minute time pointResponded to treatment at the 60 minute time point
Stage I: One Spray CTY-5339-A8910101010101099987766
Stage I: One Spray CTY-5339-CB810101010108442211111
Stage I: One Spray CTY-5339-P4333233222222222

Stage I: Sum of Pain Intensity Differences (SPID) for Pin Prick Test (PPT) (Post-hoc)

"SPID was calculated as a sum of the delta PPT scores at each time point until the designated time point. The delta PPT score is defined as the change in PPT score from baseline. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -100 (best) to +100 (worst) for SPID at the 30 minute time point, and from -160 (best) to +160 (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

,,
Interventionscore (Mean)
SPID at the 30 minute time pointSPID at the 60 minute time point
Stage I: One Spray CTY-5339-A-82.1-128.1
Stage I: One Spray CTY-5339-CB-37.8-44.0
Stage I: One Spray CTY-5339-P-29.3-53.3

Stage I: Sum of Temperature Differences (STID) for Heat Sensation Threshold (QST Heat) (Post-hoc)

"STID was calculated as a sum of the delta QST Heat scores at each time point until the designated time point. The delta QST Heat score is defined as the change in QST Heat score from baseline. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -155 ºC (best) to +155 ºC (worst) for STID at the 30 minute time point, and from -248 ºC (best) to +248 ºC (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage I outcome." (NCT03233737)
Timeframe: Up to one hour post-application

,,
InterventionDegrees Celcius (ºC) (Mean)
STID at the 30 minute time pointSTID at the 60 minute time point
Stage I: One Spray CTY-5339-A153.0320.2
Stage I: One Spray CTY-5339-CB10.426.1
Stage I: One Spray CTY-5339-P72.5134.6

Stage II: Percentage of Responders for Heat Sensation Threshold (QST Heat) at Each Time Point

"Response at a time point is defined as an increase of QST heat pain temperature by ≥ 3 degrees C compared to the Baseline QST.~QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

,
InterventionParticipants (Count of Participants)
Responded to treatment at the 1 minute time pointResponded to treatment at the 2 minute time pointResponded to treatment at the 3 minute time pointResponded to treatment at the 4 minute time pointResponded to treatment at the 5 minute time pointResponded to treatment at the 10 minute time pointResponded to treatment at the 15 minute time pointResponded to treatment at the 20 minute time pointResponded to treatment at the 25 minute time pointResponded to treatment at the 30 minute time pointResponded to treatment at the 35 minute time pointResponded to treatment at the 40 minute time pointResponded to treatment at the 45 minute time pointResponded to treatment at the 50 minute time pointResponded to treatment at the 55 minute time pointResponded to treatment at the 60 minute time point
One Spray CTY-5339-A36373737373838363228242219171413
One Spray CTY-5339-CB2930303031343129241915151212119

Stage II: Percentage of Responders for Pin Prick Test (PPT) at Each Time Point

"Response at at time point is defined as when the PPT average pain score was less than the Baseline PPT average score by any amount. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

,
InterventionParticipants (Count of Participants)
Responded to treatment at the 1 minute time pointResponded to treatment at the 2 minute time pointResponded to treatment at the 3 minute time pointResponded to treatment at the 4 minute time pointResponded to treatment at the 5 minute time pointResponded to treatment at the 10 minute time pointResponded to treatment at the 15 minute time pointResponded to treatment at the 20 minute time pointResponded to treatment at the 25 minute time pointResponded to treatment at the 30 minute time pointResponded to treatment at the 35 minute time pointResponded to treatment at the 40 minute time pointResponded to treatment at the 45 minute time pointResponded to treatment at the 50 minute time pointResponded to treatment at the 55 minute time pointResponded to treatment at the 60 minute time point
One Spray CTY-5339-A47505049494949494846433632252019
One Spray CTY-5339-CB46484848494948464542342721202018

Stage II: Sum of Pain Intensity Differences (SPID) for Pin Prick Test (PPT) (Post-hoc)

"SPID was calculated as a sum of the delta PPT scores at each time point until the designated time point. The delta PPT score is defined as the change in PPT score from baseline. PPT scores were assessed using a 0 (no pain) to 10 (severe pain) Numerical Rating Scale at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -100 (best) to +100 (worst) for SPID at the 30 minute time point, and from -160 (best) to +160 (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

,
Interventionscore (Mean)
SPID at the 30 minute time pointSPID at the 60 minute time point
One Spray CTY-5339-A-85.2-122.6
One Spray CTY-5339-CB-63.2-86.6

Stage II: Sum of Temperature Differences (STID) for Heat Sensation Threshold (QST Heat) (Post-hoc)

"STID was calculated as a sum of the delta QST Heat scores at each time point until the designated time point. The delta QST Heat score is defined as the change in QST Heat score from baseline. QST Heat scores were the temperature where the sensation of a heat stimuli was felt: ranging from 35 ºC to a maximum of 50.5 ºC with intervals of 0.5 ºC, at a frequency of every 1 minute for the first 5 minutes and then every 5 minutes thereafter until the final 60 minute time point.~The total possible scale range was from -155 ºC (best) to +155 ºC (worst) for STID at the 30 minute time point, and from -248 ºC (best) to +248 ºC (worst) for SPID at the 60 minute time point Lower scores signify a better outcome (less sensitive to pain than at baseline = less pain with therapy = therapy was more effective).~Stage II outcome." (NCT03233737)
Timeframe: Up to one hour post-application

,
InterventionDegrees Celcius (ºC) (Mean)
STID at the 30 minute time pointSTID at the 60 minute time point
One Spray CTY-5339-A136.5214
One Spray CTY-5339-CB96.6149.1

Change in Pain Score

The primary outcome is the difference in pain score using a validated visual analog scale before the procedure, which is designated as the pre-procedure (or baseline) pain score to the maximum pain during procedure (designated as time 0) These two pain scores will be subtracted and the change in pain score will be reported. The validated visual analog scale allows patients to report pain on a scale of 0 to 100 mm long. At the beginning and at the end, there are two descriptors representing extremes of pain (i.e. no pain = 0 and extreme pain = 100). The patient rated her pain by making a vertical mark on the 100-mm line. The measurement in millimeters was converted to the same number of points ranging from 0 to 100 points. There are no subgroups. (NCT01925469)
Timeframe: Pre-procedure (Baseline) and procedure (Time 0)

Interventionmm (Median)
Benzocaine50.6
Saline Spray70.4

Change in Pain Score From Pre-procedure to 5 Minutes Post Procedure.

The patients pain scores will also be assessed at 5 minutes post procedure and the change in pain scores from baseline to this time points will be analyzed. The pain scores will be subtracted to obtain the change in pain score (NCT01925469)
Timeframe: 5 minutes

Interventionmm (Median)
Benzocaine-11.1
Saline Spray-37

Patient Satisfaction

The patient's satisfaction will be assessed using a validated satisfaction scale 30 minutes post procedure. (NCT01925469)
Timeframe: 30 minutes post procedure

,
Interventionparticipants (Number)
Extremely satisfiedVery satisfiedSatisfied
Benzocaine1022
Saline Spray1040

Reviews

2 reviews available for benzocaine and Pain

ArticleYear
Intraoperative detection of methemoglobinemia in a patient given benzocaine spray to relieve discomfort from a nasogastric tube: a case report.
    AANA journal, 2008, Volume: 76, Issue:2

    Topics: Accidental Falls; Administration, Oral; Adult; Aerosols; Anesthetics, Local; Benzocaine; Blood Gas A

2008
Does circumcision of the newborn require an anesthetic?
    Clinical pediatrics, 1968, Volume: 7, Issue:3

    Topics: Anesthetics, Local; Benzocaine; Child Development; Circumcision, Male; Humans; Infant, Newborn; Male

1968

Trials

27 trials available for benzocaine and Pain

ArticleYear
Evaluating the Preemptive Analgesic Effect of Photo-biomodulation Therapy on Pain Perception During Local Anesthesia Injection in Children: A Split-mouth Triple-blind Randomized Controlled Clinical Trial.
    Photochemistry and photobiology, 2022, Volume: 98, Issue:5

    Topics: Analgesics; Anesthesia, Local; Anesthetics, Local; Benzocaine; Child; Gels; Humans; Lidocaine; Mouth

2022
Efficacy and safety of a triple active sore throat lozenge in the treatment of patients with acute pharyngitis: Results of a multi-centre, randomised, placebo-controlled, double-blind, parallel-group trial (DoriPha).
    International journal of clinical practice, 2018, Volume: 72, Issue:12

    Topics: Acute Disease; Administration, Oral; Adult; Benzalkonium Compounds; Benzocaine; Deglutition; Double-

2018
A Proof-of-concept Study Using Quantitative Sensory Threshold Analysis to Compare Two Intraoral Topical Anesthetics.
    Clinical therapeutics, 2019, Volume: 41, Issue:2

    Topics: Administration, Topical; Adolescent; Adult; Anesthetics, Local; Benzocaine; Cross-Over Studies; Doub

2019
Role of duodenal mucosal nerve endings in the acid-induced duodenogastric sensorimotor reflex: effect of benzocaine in healthy humans.
    Neurogastroenterology and motility, 2013, Volume: 25, Issue:5

    Topics: Acids; Adult; Anesthetics, Local; Benzocaine; Cross-Over Studies; Double-Blind Method; Duodenum; Dys

2013
Randomized controlled trial of benzocaine versus placebo spray for pain relief at hysterosalpingogram.
    Reproductive biomedicine online, 2014, Volume: 28, Issue:6

    Topics: Adult; Benzocaine; Double-Blind Method; Female; Humans; Hysterosalpingography; Pain; Pain Measuremen

2014
A double-blind, randomized clinical study to determine the efficacy of benzocaine 10% on histamine-induced pruritus and UVB-light induced slight sunburn pain.
    The Journal of dermatological treatment, 2015, Volume: 26, Issue:4

    Topics: Administration, Topical; Adult; Benzocaine; Double-Blind Method; Histamine; Humans; Male; Ointments;

2015
Evaluation of 2-Stage Injection Technique in Children.
    Anesthesia progress, 2016,Spring, Volume: 63, Issue:1

    Topics: Administration, Buccal; Adolescent; Anesthesia, Dental; Anesthetics, Local; Benzocaine; Child; Child

2016
The effect of benzocaine and ketoprofen gels on pain during fixed orthodontic appliance treatment: a randomised, double-blind, crossover trial.
    Australian orthodontic journal, 2016, Volume: 32, Issue:1

    Topics: Adolescent; Adult; Anesthetics, Local; Anti-Inflammatory Agents, Non-Steroidal; Benzocaine; Cross-Ov

2016
Effect of 5% benzocaine gel on relieving pain caused by fixed orthodontic appliance activation. A double-blind randomized controlled trial.
    Orthodontics & craniofacial research, 2016, Volume: 19, Issue:4

    Topics: Adolescent; Adult; Analgesics; Benzocaine; Cross-Over Studies; Double-Blind Method; Female; Gels; Gi

2016
Comparative efficacy of 2 topical anesthetics for the placement of orthodontic temporary anchorage devices.
    Anesthesia progress, 2009,Autumn, Volume: 56, Issue:3

    Topics: Adolescent; Adult; Aged; Anesthesia, Dental; Anesthetics, Combined; Anesthetics, Local; Benzocaine;

2009
Double-blind comparison of two types of benzocaine lozenges for the treatment of acute pharyngitis.
    Arzneimittel-Forschung, 2010, Volume: 60, Issue:5

    Topics: Acute Disease; Administration, Oral; Adolescent; Adult; Aged; Anesthetics, Local; Benzocaine; Chemis

2010
Effect of topical anesthesia on pain during infiltration injection and success of anesthesia for maxillary central incisors.
    Journal of endodontics, 2012, Volume: 38, Issue:12

    Topics: Administration, Topical; Adult; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Benzocain

2012
Effectiveness of two flavored topical anesthetic agents in reducing injection pain in children: a comparative study.
    The Journal of clinical pediatric dentistry, 2012,Fall, Volume: 37, Issue:1

    Topics: Anesthesia, Dental; Anesthesia, Local; Anesthetics, Combined; Anesthetics, Local; Benzocaine; Child;

2012
Influence of site preparation methods on the pain reported during palatal infiltration using the Wand Local Anesthetic System.
    American journal of dentistry, 2003, Volume: 16, Issue:3

    Topics: Administration, Topical; Adult; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Benzocain

2003
Topical analgesia for endometrial biopsy: a randomized controlled trial.
    Obstetrics and gynecology, 2005, Volume: 106, Issue:1

    Topics: Administration, Topical; Adult; Aged; Anesthetics, Local; Benzocaine; Biopsy, Needle; Double-Blind M

2005
Reduction of pain from needle stick in the oral mucosa by topical anesthetics: a comparative study between lidocaine/prilocaine and benzocaine.
    The Journal of clinical dentistry, 2005, Volume: 16, Issue:2

    Topics: Adult; Anesthetics, Combined; Anesthetics, Local; Benzocaine; Cuspid; Humans; Lidocaine; Lidocaine,

2005
Comparison of topical anesthetics (EMLA/Oraqix vs. benzocaine) on pain experienced during palatal needle injection.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2007, Volume: 103, Issue:5

    Topics: Adult; Anesthesia, Dental; Anesthesia, Local; Anesthetics, Local; Benzocaine; Gels; Humans; Injectio

2007
Efficacy of Auralgan for treating ear pain in children with acute otitis media.
    Archives of pediatrics & adolescent medicine, 1997, Volume: 151, Issue:7

    Topics: Acute Disease; Adolescent; Adult; Antipyrine; Benzocaine; Child; Child, Preschool; Double-Blind Meth

1997
Topical benzocaine anaesthesia lacks analgesic effects in painful non-acid oesophagitis.
    Alimentary pharmacology & therapeutics, 1997, Volume: 11, Issue:5

    Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Analgesia; Anesthetics, Local; Benzocaine;

1997
Ineffectiveness of topical benzocaine spray during colposcopy.
    The Journal of family practice, 1998, Volume: 46, Issue:3

    Topics: Administration, Topical; Adult; Anesthetics, Local; Anxiety; Benzocaine; Biopsy; Cervix Uteri; Colpo

1998
Comparison of epidural butamben to celiac plexus neurolytic block for the treatment of the pain of pancreatic cancer.
    The Clinical journal of pain, 2000, Volume: 16, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Analgesia, Epidural; Anesthetics, Local; Benzocaine; Celiac Plexus;

2000
Clinical evaluation and comparison of 2 topical anesthetics for pain caused by needle sticks and scaling and root planing.
    Journal of periodontology, 2001, Volume: 72, Issue:4

    Topics: Administration, Topical; Adult; Aged; Anesthetics, Local; Benzocaine; Bicuspid; Dental Arch; Dental

2001
Clinical effectiveness of lidocaine and benzocaine for topical anesthesia.
    Anesthesia progress, 1999,Summer, Volume: 46, Issue:3

    Topics: Adolescent; Adult; Analysis of Variance; Anesthesia, Local; Anesthetics, Local; Benzocaine; Double-B

1999
A double-blind crossover comparison of topical anesthetics.
    Journal of the American Dental Association (1939), 1979, Volume: 98, Issue:2

    Topics: Administration, Topical; Adult; Anesthetics, Local; Benzocaine; Clinical Trials as Topic; Double-Bli

1979
A clinical evaluation of three topical anaesthetic agents.
    Australian dental journal, 1992, Volume: 37, Issue:4

    Topics: Adult; Anesthetics, Local; Benzocaine; Double-Blind Method; Drug Combinations; Female; Humans; Injec

1992
Comparison of the effectiveness of two topical anesthetics and a placebo in reducing injection pain.
    Hawaii dental journal, 1985, Volume: 16, Issue:12

    Topics: Administration, Topical; Anesthetics, Local; Benzocaine; Humans; Injections; Pain; Placebos

1985
Double-blind controlled trial of a throat spray containing benzocaine and cetalkonium chloride on postoperative adult tonsillectomy patients.
    The British journal of clinical practice, 1970, Volume: 24, Issue:6

    Topics: Adult; Anti-Infective Agents, Local; Benzocaine; Clinical Trials as Topic; Humans; Pain; Postoperati

1970

Other Studies

22 other studies available for benzocaine and Pain

ArticleYear
Topical Cetacaine is probably more effective in preventing pain than benzocaine and an eutectic mixture of local anesthetic before palatal infiltration in children.
    Journal of the American Dental Association (1939), 2020, Volume: 151, Issue:10

    Topics: Administration, Topical; Anesthetics, Local; Benzalkonium Compounds; Benzocaine; Cetrimonium Compoun

2020
Effect of pre-cooling agent on intensity of pricking pain at intraoral injection site in adults: An experimental study.
    JPMA. The Journal of the Pakistan Medical Association, 2021, Volume: 71, Issue:5

    Topics: Adult; Anesthesia, Local; Anesthetics, Local; Benzocaine; Female; Humans; Male; Pain; Pain Measureme

2021
Making chorionic villus sampling painless for both the patient and the physician.
    Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine, 2014, Volume: 33, Issue:2

    Topics: Administration, Topical; Anesthetics, Local; Benzocaine; Chorionic Villi Sampling; Female; Humans; I

2014
Development, characterization, and in vitro and in vivo evaluation of benzocaine- and lidocaine-loaded nanostructrured lipid carriers.
    Journal of pharmaceutical sciences, 2011, Volume: 100, Issue:5

    Topics: Analgesics; Anesthetics, Local; Animals; Benzocaine; Drug Carriers; Humans; Lidocaine; Lipids; Male;

2011
Long buccal nerve block injection pain in patients with irreversible pulpitis.
    Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics, 2011, Volume: 112, Issue:1

    Topics: Adolescent; Adult; Age Factors; Aged; Anesthetics, Local; Benzocaine; Cheek; Epinephrine; Female; Hu

2011
Poly(lactide-co-glycolide) nanocapsules containing benzocaine: influence of the composition of the oily nucleus on physico-chemical properties and anesthetic activity.
    Pharmaceutical research, 2011, Volume: 28, Issue:8

    Topics: Anesthetics, Local; Animals; Benzocaine; Cellulose; Chemistry, Pharmaceutical; Drug Carriers; Hydrog

2011
Inhibition of sensory neuronal TRPs contributes to anti-nociception by butamben.
    Neuroscience letters, 2012, Jan-11, Volume: 506, Issue:2

    Topics: Anesthetics, Local; Animals; Benzocaine; HEK293 Cells; Humans; Pain; Patch-Clamp Techniques; Sensory

2012
Relief of palatal injection pain by liposome-encapsulated 2% lignocaine prepared by ultrasonic dental scaler.
    The British journal of oral & maxillofacial surgery, 2012, Volume: 50, Issue:8

    Topics: Adult; Anesthesia, Dental; Anesthetics, Local; Benzocaine; Female; Humans; Injections; Lidocaine; Li

2012
Kv1.1 channels of dorsal root ganglion neurons are inhibited by n-butyl-p-aminobenzoate, a promising anesthetic for the treatment of chronic pain.
    The Journal of pharmacology and experimental therapeutics, 2003, Volume: 304, Issue:2

    Topics: Action Potentials; Anesthetics, Local; Animals; Benzocaine; Cells, Cultured; Chronic Disease; Gangli

2003
Bye-bye benzocaine?
    Nursing, 2003, Volume: 33, Issue:7

    Topics: 4-Aminobenzoic Acid; Anesthetics, Local; Benzalkonium Compounds; Benzocaine; Cetrimonium Compounds;

2003
[Danger in the use of procaine with butyl aminobenzoate in thoracic surgery].
    Le Poumon, 1954, Volume: 10, Issue:2

    Topics: Aminobenzoates; Analgesia; Anesthesia; Anesthesia and Analgesia; Benzocaine; Pain; Pain Management;

1954
Prolonged local analgesia with benzocaine-urethane solution.
    British medical journal, 1954, Sep-18, Volume: 2, Issue:4889

    Topics: Abdomen; Aminobenzoates; Amputation Stumps; Analgesia; Benzocaine; Pain; Pain Management; Urethane

1954
Benzocaine-urethane solution in ophthalmology.
    The British journal of ophthalmology, 1958, Volume: 42, Issue:10

    Topics: Aminobenzoates; Analgesia; Anesthesia; Anesthesia and Analgesia; Anesthesia, Conduction; Benzocaine;

1958
Effectiveness of 20% benzocaine as a topical anesthetic for intraoral injections.
    Anesthesia progress, 2003, Volume: 50, Issue:4

    Topics: Administration, Topical; Adolescent; Adult; Anesthetics, Local; Benzocaine; Female; Humans; Injectio

2003
Decreased efficacy of topical anesthetic creams in presence of benzoyl peroxide.
    Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2005, Volume: 31, Issue:11 Pt 1

    Topics: Administration, Topical; Anesthetics, Local; Benzocaine; Benzoyl Peroxide; Drug Interactions; Humans

2005
Cost analysis of a mucoadhesive foam versus conventional treatment for postepisiotomy patients.
    Hospital formulary, 1986, Volume: 21, Issue:12

    Topics: Aerosols; Benzocaine; Cost-Benefit Analysis; Edema; Episiotomy; Female; Humans; Hydrocortisone; Pain

1986
Unexpected cyanosis in the surgical patient.
    Surgical endoscopy, 2000, Volume: 14, Issue:6

    Topics: Adult; Anesthetics, Local; Benzocaine; Cyanosis; Endoscopy; Female; Humans; Intubation, Gastrointest

2000
Treating the discomfort of oral ulceration resulting from cancer chemotherapy.
    Compendium of continuing education in dentistry (Jamesburg, N.J. : 1995), 1999, Volume: 20, Issue:4

    Topics: Adult; Anesthetics, Local; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Be

1999
Pain relief in hysterosalpingography. A comparison of analgesics.
    The Journal of reproductive medicine, 1990, Volume: 35, Issue:5

    Topics: Analgesics; Benzocaine; Dose-Response Relationship, Drug; Drug Combinations; Female; Gels; Humans; H

1990
[Anesthetic and medicated ointments].
    Zahnarztliche Praxis, 1974, Oct-04, Volume: 25, Issue:19

    Topics: Analgesics; Benzocaine; Gingiva; Gingivitis; Humans; Mouth Mucosa; Ointments; Pain; Stomatitis

1974
Clinical investigation of the use of benzocaine in orabase.
    Journal - Connecticut State Dental Association, 1968, Volume: 42, Issue:3

    Topics: Anesthesia, Dental; Benzocaine; Dentistry; Methylcellulose; Mouth Diseases; Occlusive Dressings; Oin

1968
[Drug therapy of post extraction pain].
    Deutsche Stomatologie, 1970, Volume: 20, Issue:5

    Topics: Adolescent; Adult; Aged; Benzocaine; Child; Dry Socket; Humans; Middle Aged; Ointments; Pain; Postop

1970